Background:
This study assessed the effectiveness of Yangxin Decoction (YXD) in the treatment of coronary heart disease (CHD) patients with angina pectoris (AP).
Methods:
In this study, we systematically and comprehensively searched the PUBMED, EMBASE, Cochrane Library, CNKI, WANGFANG, and VIP databases from their establishment to June 1, 2022. Clinical randomized controlled trials of YXD for the management of AP in patients with CHD were considered for inclusion. The outcomes included the response rate of AP, response rate based on electrocardiogram, and the rate of nitroglycerin use. Two authors independently performed literature selection, data extraction, and methodological quality assessment. Any differences were resolved by a third author through a discussion.
Results:
Nine trials involving 819 patients were included. The meta-analysis results showed that YXD significantly improved the response rate of AP (OR = 2.98, 95% CI: 1.96–4.55, I2 = 0%, P < .01) and the response rate based on the electrocardiogram (OR = 1.88, 95% CI: 1.28–2.78, I2 = 26%, P < .01), and significantly reduced the rate of nitroglycerin use (OR = 2.04, 95% CI: 1.19–3.52, I2 = 0%, P = .01).
Conclusions:
The results of this study showed that YXD was effective in the treatment of patients with AP of CHD. Further studies are required to confirm these results.
Keywords: angina pectoris, coronary heart disease, effectiveness, meta-analysis, randomized controlled trial, systematic review, Yangxin decoction
1. Introduction
Coronary heart disease (CHD) is one of the most common heart disorders that seriously threatens public health.[1–4] It is also one of the leading causes of death globally.[4–6] Its prevalence is increasing annually, accounting for over 40% of all deaths.[6–8] Therefore, more attention should be paid to this issue in future studies.
Angina pectoris (AP) is a major CHD.[9–11] It consists of 2 types: stable and unstable angina.[12,13] According to theory of traditional Chinese medicine (TCM), AP belongs to the “Xiong Bi,” “chest arthralgia,” and “heartache.” Its major pathogenesis is explained by “heart pulse stasis” and “Qi statsis.”[14–20] Clinical practice has proven that Yangxin Decoction (YXD) has unique advantages for the management of patients with AP of CHD.[21–29]
Previous studies have reported that YXD can improve the AP of CHD by increasing the levels of serum 6-Keto-PGF 1α, high-density lipoprotein cholesterol, and apolipoprotein A.[30,31] It can also enhance myocardial function and aortic abnormalities.[32] Another study found that YXD can protect the ischemic myocardium by regulating vascular endothelial function, improving nitric oxide and nitric oxide synthase production, and decreasing TXB2 production.[33]
A variety of clinical studies have reported the effectiveness of YXD in the treatment of patients with AP of CHD.[21–29] However, there is insufficient evidence-based medicine evidence to systematically and comprehensively investigate its effectiveness on patients with AP of CHD. Therefore, this study aimed to systematically evaluate the clinical effectiveness of YXD in the management of patients with AP of CHD.
2. Methods
2.1. Ethical statement
This study did not involve any individual data; therefore, no ethical approval was required for this systematic review.
2.2. Eligibility criteria
2.2.1. Inclusion criteria.
This study included randomized controlled trials (RCTs) of YXD in patients with AP of CHD. The patient was diagnosed with AP of CHD. Patients in the control group received routine treatment, whereas those in the treatment group were treated with YXD based on the control group. The outcomes were the response rate of AP, the response rate based on electrocardiogram, and the rate of nitroglycerin use.
2.2.2. Exclusion criteria.
The exclusion criteria were as follows: repetitive publications, nonclinical trials, case reports, case series, noncontrolled trials, quasi-RCTs, wrong comparisons, non-RCTs, studies with insufficient data and unavailable data reporting, and unclear diagnosis and treatment course.
2.3. Literature retrieval
PUBMED, EMBASE, Cochrane Library, CNKI, WANGFANG, and VIP databases were searched from inception to June 1, 2022. In addition, we checked the reference lists of relevant reviews to avoid omitting potential RCTs. The search terms included “coronary heart disease,” “coronary disease,” “atherosclerosis,” “angina pectoris,” “stable angina pectoris,” “angina, stable,” “angina, unstable,” “microvascular angina,” “Yangxin decoction,” “randomized controlled trial,” “controlled trials,” “clinical trials,” “random,” and “randomly.”
2.4. Literature selection and data collection
Two authors independently selected the literature by scanning titles/abstracts and carefully reading the full-text against the eligibility criteria. Two authors independently collected data from the included trials. This included publication information (title, first author, year of publication, and published journal), methodological quality (study design type, randomization method, allocation, blinding details, and outcome report), intervention and control details (modality type, treatment course, and dose), and associated outcomes. Any divergence was resolved by discussion or consultation with a third author.
2.5. Study methodological quality assessment
Two reviewers independently evaluated the study quality using the Cochrane Risk of Bias Tool. We investigated each study using 7 domains, and each was further judged as having a high, unclear, or low risk of bias. A third author helped to resolve any differences through discussion or consultation.
2.6. Statistical analysis
RevMan 5.4 software (Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration) was used for the statistical analysis. The dichotomous data are presented as odds ratios (OR). Continuous data were calculated as mean difference and 95% confidence interval (CI). Heterogeneity across the included RCTs was checked using I² statistics. I² ≤50% suggested acceptable heterogeneity, and a fixed-effects model was used. I² >50% indicated significant heterogeneity, and a random-effects model was used. We conducted a meta-analysis if sufficient data were collected on the same outcomes. Otherwise, we reported the associated results using a narrative and descriptive summary.
3. Results
3.1. Study selection
As shown in Figure 1, 913 records were retrieved. Of these, 447 duplicate records were excluded from the analysis. After scanning the titles, abstracts, and full papers, 9 RCTs were finally included in this study (Fig. 1).
Figure 1.
Flow chart of study selection.
3.2. General characteristics
All 9 included RCTs were published in China, and 819 patients diagnosed with CHD and AP were included in this study (Table 1). All control groups received routine treatment and all treatment groups received YXD and routine treatment. The treatment course lasted for 2–8 weeks. The characteristics of the 9 RCTs are listed in Table 1.
Table 1.
General characteristics of included randomized controlled trials.
| Study | Sample size (T/C) | Age (yrs, T/C) | Gender (M/F) | Intervention | Control | Outcomes | Treatment course |
|---|---|---|---|---|---|---|---|
| Jia 2020 [21] | 26/25 | T:52.3 ± 4.1 | T:14/12 | YXD plus Routine treatment | Routine treatment | ① | 4 wks |
| C:53.1 ± 4.3 | C:14/11 | ||||||
| Liu 2019 [22] | 40/35 | T:64.8 ± 7.5 | T:23/17 | YXD plus Routine treatment | Routine treatment | ② | 4 wks |
| C:64.5 ± 7.7 | C:20/14 | ||||||
| Wu 2012[23] | 49/48 | T:50.2 ± 8.6 | T:26/23 | YXD plus Routine treatment | Routine treatment | ①② | 4 wks |
| C:51.2 ± 8.5 | C:28/20 | ||||||
| Xie 2018[24] | 75/75 | T:56.6 ± 5.5 | T:40/35 | YXD plus Routine treatment | Routine treatment | ① | 8 wks |
| C:57.0 ± 5.7 | C:41/34 | ||||||
| Yu 2011[25] | 53/50 | T:59.7 ± 1.4 | T:21/32 | YXD plus Routine treatment | Routine treatment | ①②③ | 4 wks |
| C:60.1 ± 1.2 | C:20/30 | ||||||
| Yu 2012[26] | 58/57 | T:58.1 ± 4.3 | T:32/26 | YXD plus Routine treatment | Routine treatment | ①②③ | 4 wks |
| C:58.4 ± 4.0 | C:30/27 | ||||||
| Yu 2018[27] | 52/48 | T:55.3 ± 5.1 | T:32/20 | YXD plus Routine treatment | Routine treatment | ①② | 4 wks |
| C:57.2 ± 11.7 | C:31/17 | ||||||
| Zhai 2014[28] | 30/30 | 56.8* | 27/33 | YXD plus Routine treatment | Routine treatment | ①②③ | 4 wks |
| Zhu 2013[29] | 34/34 | T:59.5 ± 6.7 | T:19/15 | YXD plus Routine treatment | Routine treatment | ① | 2 wks |
| C:59.9 ± 6.1 | C:20/14 |
①: effect rate of angina pectoris; ②: effect rate based on electrocardiogram; ③: nitroglycerin rate.
Age reported as mean age.
C = control group, F = female, M = Male, T = treatment group, YXD = Yangxin decoction.
3.3. Study quality assessment
All 9 RCTs[21–29] described the randomization details sufficiently (Fig. 2). Four studies reported an adequate allocation.[23,25,26,29] All studies also provided sufficient information on incomplete outcome data, selective reporting, and other bias.[21–29] However, none of these studies provided sufficient information regarding blindness[21–29] (Fig. 2).
Figure 2.
Risk of bias summary.
3.4. Meta-analysis of response rate of AP
Eight studies involving 744 patients reported the response rate for AP.[21,23–29] No heterogeneity across the 8 studies was detected (I2 = 0%, P = .46); therefore, a fixed-effects model was utilized. The results showed that YXD combined with routine treatment was better than the control group in enhancing the response rate of AP, and the difference was statistically significant (OR = 2.98, 95% CI: 1.96–4.55, P < .01) (Fig. 3).
Figure 3.
Meta-analysis of response rate of AP of CHD. CHD = coronary heart disease.
3.5. Meta-analysis of response rate based on electrocardiogram
Six studies involving 550 patients reported the response rate based on the electrocardiogram. Heterogeneity among the 6 trials was small (I2 = 26%, P = .24); therefore, we used a fixed-effects model to pool the data. The difference was statistically significant (OR = 1.88, 95% CI: 1.28–2.78, P < .01), indicating that YXD combined with routine treatment for AP in CHD was better than that in the control group (Fig. 4).
Figure 4.
Meta-analysis of response rate based on electrocardiogram.
3.6. Meta-analysis of nitroglycerin rate
Three studies involving 250 patients reported the rate of nitroglycerin use. There was no heterogeneity among the studies (I2 = 0%, P = .58), a fixed-effects model was used. This difference was statistically significant (OR = 2.04, 95% CI: 1.19–3.52, P = .01) (Fig. 5).
Figure 5.
Meta-analysis of rate of nitroglycerin use.
4. Discussion
AP in CHD is a clinical manifestation of myocardial ischemia, hypoxia, or necrosis due to an insufficient coronary blood supply. When it attacks, patients often experience retrosternal crushing pain that radiates to the shoulder and back. Studies have shown that AP of CHD tends to occur in middle-aged or older people. TCM has been reported to be effective in managing AP in CHD patients.
Previous similar studies have reported that YXD can effectively relieve the symptoms of patients with AP of CHD.[34–36] However, the overall methodological quality of the included trials was very poor, which may have affected the robustness and reliability of these studies.[34–36] Thus, it is necessary to conduct an updated study with a higher quality of the included studies.
The results of this study are partly consistent with those of previous studies.[34–36] This systematic review of RCTs included a total of 9 trials involving 819 patients with AP of CHD. This study investigated the effectiveness of YXD in combination with routine treatment compared with routine treatment for the management of patients with AP of CHD. The results showed that YXD had better outcomes in improving the response rate of AP, response rate based on an electrocardiagram, and reduction of the rate of nitroglycerin use.
This systematic review has several limitations: (1) according to the evaluation of the Cochrane Risk of Bias Tool, the quality of included trials is still not too high, although it is higher than that in previous studies.[34–36] Five studies did not report allocation concealment and none of the included studies reported blinding procedures. (2) No placebo or sham intervention was applied to the control group in any of the included trials, which may have affected the efficacy evaluation in this study. (3) All the included studies were conducted and published in China, which may have affected the risk of publication bias. Future studies should address these limitations in the future.
5. Conclusion
The results of this study showed that the application of YXD can benefit CHD patients with AP. Future studies with more high quality trials are needed to warrant the present findings.
Author contributions
Conceptualization: Xiao-hong Yu and Zhe-ming Xu.
Data curation: Xiao-hong Yu and Zhe-ming Xu.
Formal analysis:Xiao-hong Yu, Xi-wen Yu, and Hai-xiang Li.
Investigation: Zhe-ming Xu.
Methodology: Xiao-hong Yu, Xi-wen Yu, and Hai-xiang Li.
Supervision: Zhe-ming Xu.
Validation: Xi-wen Yu and Hai-xiang Li.
Writing–original draft: Xiao-hong Yu and Zhe-ming Xu.
Writing–review & editing: Xiao-hong Yu and Zhe-ming Xu.
Abbreviations:
- AP =
- angina pectoris
- CHD =
- coronary heart disease
- CI =
- confidence interval
- RCTs =
- clinical randomized controlled trials
- TCM =
- traditional Chinese medicine
- YXD =
- Yangxin decoction
X.-h.Y. and X.-w.Y. have contributed equally to this study.
The authors have no conflicts of interest to disclose.
All authors state that they do not have any completing interests in this study.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
This study was partly supported by Heilongjiang University of Traditional Chinese Medicine Scientific Research Project of “Excellent Innovative Talents Support Plan” (2018RCQ02). The supporter did not involve in this study.
How to cite this article: Yu X-H, Yu X-W, Xu Z-M, Li H-X. Yangxin decoction for the treatment of angina pectoris of coronary heart disease: A systematic review of randomized controlled trial. Medicine 2022;101:35(e30394).
Contributor Information
Xiao-hong Yu, Email: 1170861406@qq.com.
Xi-wen Yu, Email: 1170861406@qq.com.
Hai-xiang Li, Email: 106089899@qq.com.
References
- [1].Li X, Da Z, Ren X, et al. Trends and distribution of coronary heart disease mortality rate in Hexi Corridor, Gansu, China from 2006 to 2015. Rev Cardiovasc Med. 2021;22:1003–8. [DOI] [PubMed] [Google Scholar]
- [2].Winning L, Patterson CC, Linden K, et al. Periodontitis and risk of prevalent and incident coronary heart disease events. J Clin Periodontol. 2020;47:1446–56. [DOI] [PubMed] [Google Scholar]
- [3].Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387:251–72. [DOI] [PubMed] [Google Scholar]
- [4].Xiong XJ, Wang Z, Wang J. Innovative strategy in treating angina pectoris with Chinese patent medicines by promoting blood circulation and removing blood stasis: experience from combination therapy in Chinese medicine. Curr Vasc Pharmacol. 2015;13:540–53. [DOI] [PubMed] [Google Scholar]
- [5].Kuller LH, Lopez OL, Mackey RH, et al. Subclinical cardiovascular disease and death, dementia, and coronary heart disease in patients 80+ years. J Am Coll Cardiol. 2016;67:1013–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Wallace LM, Theou O, Kirkland SA, et al. Accumulation of non-traditional risk factors for coronary heart disease is associated with incident coronary heart disease hospitalization and death. PLoS One. 2014;9:e90475. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [7].Zou ZQ, Liu M, Zhong HQ, et al. Association of previous schistosome infection with fatty liver and coronary heart disease: a cross-sectional study in china. Parasite Immunol. 2021;43:e12822. [DOI] [PubMed] [Google Scholar]
- [8].Kumar A, Avishay DM, Jones CR, et al. Sudden cardiac death: epidemiology, pathogenesis and management. Rev Cardiovasc Med. 2021;22:147–58. [DOI] [PubMed] [Google Scholar]
- [9].Wilke A, Noll B, Maisch B. Angina pectoris bei extrakoronaren Erkrankungen [Angina pectoris in extracoronary diseases]. Herz. 1999;24:132–9. [DOI] [PubMed] [Google Scholar]
- [10].Zhai J, Ji Z, Jin X, et al. Meta-analysis of the effect of Honghua injection in the treatment of coronary heart disease Angina Pectoris. Evid Based Complement Alternat Med. 2022;2022:4537043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].Qi WC, Fu HJ, Sun RR, et al. Effectiveness and safety of acupuncture for angina pectoris: An overview of systematic reviews. Integr Med Res. 2022;11:100864. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Huang Q, Wang SS, Luo RH. Correlation and mechanism between cardiac magnetic resonance imaging and oral streptococcus count in patients with primary microvascular angina pectoris. Medicine (Baltimore). 2022;101:e29060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13].Malta DC, Pinheiro PC, Vasconcelos NM, et al. Prevalence of Angina Pectoris and associated factors in the adult population of Brazil: national survey of health, 2019. Rev Bras Epidemiol. 2021;24(suppl 2):e210012. [DOI] [PubMed] [Google Scholar]
- [14].Yu L, Lu X, Xu C, et al. Overview of microvascular angina pectoris and discussion of traditional Chinese medicine intervention. Evid Based Complement Alternat Med. 2022;2022:1497722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15].Zhang Z, Xing W, Liu H, et al. Effects of Shen-Yuan-Dan on periprocedural myocardial injury and the number of peripheral blood endothelial progenitor cells in patients with unstable angina pectoris undergoing elective percutaneous coronary intervention. Evid Based Complement Alternat Med. 2022;2022:9055585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].Wang Y, Xu Y, Zhang L, et al. Comparison of Buyang Huanwu granules and Naoxintong capsules in the treatment of stable angina pectoris: rationale and design of a randomized, blinded, multicentre clinical trial. Trials. 2022;23:65. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [17].Qi G, Jiang K, Qu J, et al. The material basis and mechanism of Xuefu Zhuyu decoction in treating stable Angina Pectoris and unstable angina pectoris. Evid Based Complement Alternat Med. 2022;2022:3741027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [18].Geng HJ, Xie YM, Wang ZF. Clinical comprehensive evaluation of Naoxintong Capsules in treatment of cerebral infarction with Qi deficiency and blood stasis syndrome and coronary heart disease angina pectoris. China J Chin Mater Med. 2021;46:6087–95. [DOI] [PubMed] [Google Scholar]
- [19].Liu J, Dong Y, Hu X. Efficacy of Yangxin recipe in combination with conventional western medicine in treatment of Angina Pectoris of coronary heart disease. Clin Appl Thromb Hemost. 2022;28:10760296221076152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [20].Cui X, Han S, Li J, et al. Clinical comprehensive evaluation of Guanxin Shutong Capsules in treatment of coronary heart disease angina pectoris with heart blood stasis syndrome. China J Chin Mater Med. 2022;47:1469–75. [DOI] [PubMed] [Google Scholar]
- [21].Jia XJ, Yang GH. To observe the effect of Yiqi Yangxin decoction in treating 26 cases of coronary heart disease. Chin Heal Stand Admin. 2020:99–101. [Google Scholar]
- [22].Liu XC, Liu LX, Lin NM. Yangxin decoction combined with conventional Western medicine in the treatment of unstable Angina Pectoris of coronary heart disease with heart-qi deficiency. New Chin Med. 2019;51:80–3. [Google Scholar]
- [23].Wu HH. Effect of Yangxin decoction on serum miRNA-1 and urine metabonomics in patients with premature ventricular contractions (type of deficiency of Qi and blood). Heilongjiang Univ Tradit Chin Med. 2012. (Dissertation. [Google Scholar]
- [24].Xie GB, Xie Y. Therapeutic effect of Yangxin decoction combined with Atorvastatin on stable Angina Pectoris of coronary heart disease. Clin Pract Integr Chin West Med. 2018;18:11–3. [Google Scholar]
- [25].Yu XH. Clinical Study and metabolomics effect of Yangxin decoction on patients with unstable Angina pectoris. Heilongjiang Univ Tradit Chin Med. 2011. (Dissertation. [Google Scholar]
- [26].Yu XW. Effect of Yangxin decoction on TNF-Α and plasma metabolomics in patients with UA. Heilongjiang Univ Tradit Chin Med. 2012. (Dissertation. [Google Scholar]
- [27].Yu XH, Chen B, Wang YP, et al. Clinical observation of Yangxin decoction in treating unstable angina pectoris of coronary heart disease with blood stasis syndrome. Modern Chin Med Res Pract. 2018;32:70–3. [Google Scholar]
- [28].Zhai Y, Liu SR, Zhou SP. Yangxin decoction improved Angina Pectoris of coronary heart disease in 30 cases. Modern Distance Education Chin Med. 2014;12:178. [Google Scholar]
- [29].Zhu H. Observation on the curative effect of Yangxin decoction on 34 cases of unstable angina pectoris. J Fujian Univ Tradit Chin Med. 2013;23:58–9. [Google Scholar]
- [30].Han JR, Zhou YB, Liu YZ. Effect of yangxin decoction on blood lipid and plasma endothelin in rabbits with unstable angina pectoris. Chin J Trad Chin Med. 2006;13:163. [Google Scholar]
- [31].Liu YZ, Zhou YB, Han JR, et al. Effects of yangxin decoction on the contents of NO and NOS in rabbits’ myocardial ischemia model. Integr Cardiovasc. Cerebrovasc Dis. 2006;11:9789. [Google Scholar]
- [32].Liu YZ, Zhou YB, Pan XB. Effect of yangxin decoction on plasma TXB2 level and intima - media thickness of common carotid artery in rabbits with unstable angina pectoris. Integr Cardiol Cerebrovasc Dis. 2006;12:1067–8. [Google Scholar]
- [33].Zhang Q, Zhou YB, Sun J, et al. Effect of yangxin granule on matrix metalloproteinase-9 in rabbits with unstable angina pectoris. Integr Med J Cardiovasc Cerebrovasc Dis. 2009;7:669. [Google Scholar]
- [34].Li SW. Meta-analysis of clinical effect of Yangxin decoction on Angina pectoris of coronary heart disease. Heilongjiang Univ Trad Chin Med. 2020. (Dissertation. [Google Scholar]
- [35].Yu L, Li JQ, Cao LJ, et al. Systematic Review and Meta-analysis of Yangxin decoction in treating Angina pectoris of coronary heart disease. Chin Tradit Med Emer. 2019;28:961–4. [Google Scholar]
- [36].Fu P, Yao FZ, Yang JF, et al. Meta-analysis of Yangxin decoction in treating Angina pectoris of coronary heart disease. Chin J Evid-based Cardiovasc Med. 2015;7:726–30. [Google Scholar]